Smartlens

Smartlens is a clinical-stage company dedicated to revolutionizing glaucoma care. Its flagship product, miLens, is an innovative non-invasive contact lens-based device designed to monitor intraocular pressure (IOP), a pivotal risk factor for glaucoma. With strong clinical results presented at the 2023 and 2024 American Glaucoma Society meetings, commercialization of miLens is set for 2025. The company has patented its unique electronics-free sensor technology in over 40 countries, providing a competitive edge. Additionally, Smartlens' portfolio includes THERmic, an advanced non-invasive drug delivery technology aimed at personalizing therapies and preventing disease progression. Noteworthy entities such as Stanford University and key opinion leaders have backed Smartlens, evident in its recognition at the 2021 High-Tech Awards by Octane. The company's impactful technologies have garnered attention from reputable sources including Nature Medicine, Fortune, BBC, and ABC News. Smartlens envisions a future where glaucoma no longer steals individuals' vision and quality of life.